Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-001
- Development stage
- Phase 2
- Lead developer
- Neuraptive Therapeutics
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
NTX-001, developed by Neuraptive Therapeutics Inc., is an investigational nerve fusion system designed for the repair of peripheral nerve injuries. It is a kit that combines nerve fusion technology with a specialized device for use during surgical procedures. The core mechanism involves PEG-fusion, where polyethylene glycol (PEG) and sequenced reagents are applied to a freshly coapted nerve to facilitate the fusion of axonal membranes. This process aims to restore electrical signaling across severed peripheral nerves intra-operatively and prevent Wallerian degeneration, thereby accelerating functional recovery. The product has received FDA Fast Track Designation and Orphan Drug Designation for its fusogen.
- Brand names
- AxoFuse
- Other names
- AxoFuse Nerve Repair SystemNTX-001 PEG-FusionNTX001 PEG-FusionNTX 001 PEG-Fusionnerve fusion system
Beyond the preview
Go deeper on NTX-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-001.